Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.

Galeva I, Konstan MW, Higgins M, Angyalosi G, Brockhaus F, Piggott S, Thomas K, Chuchalin AG.

Curr Med Res Opin. 2013 Aug;29(8):947-56. doi: 10.1185/03007995.2013.805122. Epub 2013 Jun 5.

2.

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group.

Am J Respir Crit Care Med. 2012 Jan 15;185(2):171-8. doi: 10.1164/rccm.201105-0924OC. Epub 2011 Nov 17.

3.

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G.

Pediatr Pulmonol. 2011 Mar;46(3):230-8. doi: 10.1002/ppul.21356. Epub 2010 Oct 20.

4.

Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.

Mazurek H, Chiron R, Kucerova T, Geidel C, Bolbas K, Chuchalin A, Blanco-Aparicio M, Santoro D, Varoli G, Zibellini M, Cicirello HG, Antipkin YG.

Pediatr Pulmonol. 2014 Nov;49(11):1076-89. doi: 10.1002/ppul.22989. Epub 2014 Jan 24.

PMID:
24464974
5.

Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.

Sommerwerck U, Virella-Lowell I, Angyalosi G, Viegas A, Cao W, Debonnett L.

Curr Med Res Opin. 2016 Nov;32(11):1789-1795. Epub 2016 Sep 9.

PMID:
27435882
6.

Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8. doi: 10.1164/rccm.200712-1804OC. Epub 2008 Jul 24.

7.

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.

N Engl J Med. 1999 Jan 7;340(1):23-30.

8.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE.

J Cyst Fibros. 2011 Jan;10(1):54-61. doi: 10.1016/j.jcf.2010.10.003. Epub 2010 Nov 12.

9.

Tobramycin inhalation powder in cystic fibrosis patients: response by age group.

Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.

Respir Care. 2014 Mar;59(3):388-98. doi: 10.4187/respcare.02264. Epub 2013 Aug 27.

10.

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H.

Paediatr Drugs. 2007;9 Suppl 1:21-31.

PMID:
17536872
11.

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL.

Paediatr Drugs. 2007;9 Suppl 1:11-20.

PMID:
17536871
12.

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ.

Chest. 2009 May;135(5):1223-1232. doi: 10.1378/chest.08-1421.

13.

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.

Greenwood J, Schwarz C, Sommerwerck U, Nash EF, Tamm M, Cao W, Mastoridis P, Debonnett L, Hamed K.

Ther Adv Respir Dis. 2017 Jul;11(7):249-260. doi: 10.1177/1753465817710596.

PMID:
28614995
14.

One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.

Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G.

Pediatr Pulmonol. 2016 Apr;51(4):372-8. doi: 10.1002/ppul.23358. Epub 2015 Dec 27.

PMID:
26709158
15.
16.
17.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA.

J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13.

18.

Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.

Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, Onishko CR, Martin AJ, Linke RJ, Holmes M, Jarvinen A, Kennedy D, Colebatch KA, Hansman D, Parsons DW.

Pediatr Pulmonol. 2001 May;31(5):367-76.

PMID:
11340683
19.

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.

Elborn JS, Vataire AL, Fukushima A, Aballea S, Khemiri A, Moore C, Medic G, Hemels ME.

Clin Ther. 2016 Oct;38(10):2204-2226. doi: 10.1016/j.clinthera.2016.08.014. Epub 2016 Sep 29. Review.

20.

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Azithromycin Study Group.

JAMA. 2010 May 5;303(17):1707-15. doi: 10.1001/jama.2010.563.

PMID:
20442386

Supplemental Content

Support Center